US FDA grants fast track designation to Jardiance (empagliflozin) to improve outcomes following a heart attack

15 September 2020 - This fast track designation for empagliflozin emphasises the urgent need for potential treatments that may improve outcomes ...

Read more →

Ziopharm Oncology granted rare paediatric disease designation for controlled IL-12 for the treatment of DIPG

14 September 2020 -  -- Ziopharm Oncology today announced that the U.S. FDA has granted rare paediatric disease designation to ...

Read more →

European Medicines Agency approves safety label update for Novartis Beovu

14 September 2020 - Novartis worked with the EMA to update the Beovu (brolucizumab) label to guide physicians in their treatment ...

Read more →

Vertex announces European Medicines Agency type II variation marketing authorisation application validation for Kaftrio (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor in people with one copy of the F508del mutation

14 September 2020 - Vertex Pharmaceuticals today announced the EMA has validated a type II variation marketing authorisation application for ...

Read more →

EMA publishes agenda for 14-17 September CHMP meeting

14 September 2020 - The EMA has published a draft agenda for this week's CHMP meeting. ...

Read more →

Vaccine makers keep safety details quiet, alarming scientists

13 September 2020 - Researchers say drug companies need to be more open about how vaccine trials are run to reassure ...

Read more →

ESSA Pharma announces fast track designation granted by the FDA to EPI-7386 for the treatment of metastatic castration-resistant prostate cancer

14 September 2020 - ESSA Pharma today announced that the US FDA granted fast track designation to EPI-7386, its oral ...

Read more →

Sol-Gel Technologies announces FDA acceptance for filing of new drug application for Epsolay for the treatment of inflammatory lesions of rosacea

10 September 2020 - Potential to be first FDA-approved single-agent benzoyl peroxide prescription drug product. ...

Read more →

Mallinckrodt receives a complete response letter from the U.S. FDA for terlipressin for the treatment of hepatorenal syndrome type 1

14 September 2020 - Company remains committed to working with FDA toward an approval for this important potential therapy. ...

Read more →

Making best use of big data for public health: publication of the Big Data Steering Group workplan for 2020-21

14 September 2020 - The Big Data Steering Group set up by EMA and the Heads of Medicines Agencies has ...

Read more →

FDA grants Dupixent (dupilumab) breakthrough therapy designation for eosinophilic oesophagitis

14 September 2020 - There are currently no FDA approved treatments for this chronic type 2 inflammatory disease that damages the ...

Read more →

Pfizer CEO 'preparing' for likelihood of vaccine approval before end of year

13 September 2020 - Pharmaceutical company Pfizer is preparing for the likelihood of regulators approving the coronavirus vaccine the company ...

Read more →

Revolutionary cancer medicine Vitrakvi shrinks tumours in days

14 September 2020 - Doctors are amazed by a new cancer medicine offering Australian kids a new lease on life, but ...

Read more →

Trump pressed for plasma therapy. Officials worry, is an unvetted vaccine next?

12 September 2020 - New details of how the president has demanded faster action from health agencies help explain the intensifying ...

Read more →

Health Canada approves Tremfya (guselkumab injection), a first in class, selective interleukin 23 inhibitor for active psoriatic arthritis

10 September 2020 - Data show Tremfya significantly improved signs and symptoms in joints, skin, and soft tissue of adults with ...

Read more →